SLC5A2 and liver dysplastic nodule: Major breakthroughs over the past 5 years have included the identification of sodium-glucose cotransporter 2 (SGLT2) inhibitors as tools for DN treatment [6] and the value of specific microRNAs (miRNAs) as biomarkers for DN patient diagnosis [7].